The AI Impact with Generate:Biomedicines' Mike Nally

Business Of Biotech

We love to hear from our listeners. Send us a message.

Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersection of machine learning, biological engineering, and medicine." To get a grip on the "generative biology" work it's doing and the AI/ML impact it anticipates in the discovery and development of therapeutics, as well as clinical trials, we sat down with veteran biotech builder Mike Nally, CEO at Generate and CEO-Partner at Flagship Pioneering.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

บท

1. The Business of Biotech (00:00:00)

2. Company Impact on Humanity and Biotech (00:10:34)

3. Series C Financing and Investor Relations (00:26:47)

4. Impact of Generative AI in Biology (00:33:30)

5. Innovating Drug Discovery Through Data (00:47:11)

6. Navigating Innovation in Biotech Ecosystem (01:04:31)

7. Biotech Podcast Subscription and Community (01:13:05)